Cefpodoxime Proxetil
Formerly marketed as Vantin
Indications
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Community-acquired pneumonia | Adults & adolescents ≥12 y | Monotherapy | FDA Approved |
| Acute exacerbation of chronic bronchitis | Adults & adolescents ≥12 y | Monotherapy | FDA Approved |
| Acute maxillary sinusitis | Adults, adolescents & children ≥2 months | Monotherapy | FDA Approved |
| Pharyngitis / tonsillitis | Adults, adolescents & children ≥2 months | Monotherapy | FDA Approved |
| Uncomplicated skin & skin-structure infections | Adults & adolescents ≥12 y | Monotherapy | FDA Approved |
| Acute bacterial otitis media | Children ≥2 months | Monotherapy | FDA Approved |
| Uncomplicated gonorrhea (urethral, cervical, rectal in women) | Adults & adolescents ≥12 y | Single dose | FDA Approved |
| Uncomplicated urinary tract infection (cystitis) | Adults & adolescents ≥12 y | Monotherapy | FDA Approved |
Cefpodoxime covers penicillin-susceptible Streptococcus pneumoniae, Haemophilus influenzae (including beta-lactamase producers), Moraxella catarrhalis, S. pyogenes, methicillin-susceptible S. aureus, E. coli, K. pneumoniae, P. mirabilis, and penicillinase-producing N. gonorrhoeae. It is inactive against MRSA, penicillin-resistant pneumococci, Pseudomonas, and Enterococcus. Guidelines position cefpodoxime as an alternative agent for AOM, sinusitis, and pharyngitis in patients with non-severe penicillin allergy (AAP/IDSA).
Pediatric urinary tract infections: Cefpodoxime is used off-label for uncomplicated and complicated UTIs in pediatric patients at 5 mg/kg/dose q12h. Evidence quality: Moderate — supported by limited comparative trials and guideline mentions.
Step-down therapy for disseminated gonococcal infections: Following parenteral therapy, oral cefpodoxime 400 mg BID may complete a total course of at least 1 week. Evidence quality: Low — based on CDC guidance and clinical experience; current CDC guidelines have shifted toward different regimens.
Dosing
Adults & Adolescents (≥12 Years)
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Community-acquired pneumonia | 200 mg BID | 200 mg BID | 400 mg/day | 14-day course Tablets must be taken with food to enhance absorption |
| Acute exacerbation of chronic bronchitis | 200 mg BID | 200 mg BID | 400 mg/day | 10-day course Efficacy not established for beta-lactamase-producing H. influenzae strains |
| Acute maxillary sinusitis | 200 mg BID | 200 mg BID | 400 mg/day | 10-day course IDSA notes variable S. pneumoniae susceptibility; not recommended as monotherapy |
| Streptococcal pharyngitis / tonsillitis | 100 mg BID | 100 mg BID | 200 mg/day | 5–10 day course Does not prevent rheumatic fever |
| Uncomplicated skin & skin-structure infections | 400 mg BID | 400 mg BID | 800 mg/day | 7–14 day course Higher dose than other indications; dose-related efficacy demonstrated |
| Uncomplicated gonorrhea (urethral/cervical/anorectal in women) | 200 mg single dose | N/A | 200 mg | Single dose Not effective for pharyngeal gonorrhea; check current CDC guidelines for preferred regimens |
| Uncomplicated UTI (cystitis) | 100 mg BID | 100 mg BID | 200 mg/day | 7-day course Lower bacterial eradication rates vs some other UTI agents (FDA PI caveat) |
Pediatric Patients (2 Months–12 Years)
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Acute otitis media | 5 mg/kg BID | 5 mg/kg BID | 200 mg/dose (400 mg/day) | 5 days AAP alternative for penicillin-allergic patients |
| Streptococcal pharyngitis / tonsillitis | 5 mg/kg BID | 5 mg/kg BID | 100 mg/dose (200 mg/day) | 5–10 days |
| Acute maxillary sinusitis | 5 mg/kg BID | 5 mg/kg BID | 200 mg/dose (400 mg/day) | 10-day course |
Renal Impairment & Hemodialysis
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| CrCl ≥30 mL/min | No adjustment | Standard dosing | Per indication | t½ 3.5 h in mild RI (CrCl 50–80) |
| CrCl <30 mL/min | Standard single dose, but extend interval to q24h | Same dose, q24h | Per indication | t½ increases to 9.8 h in severe RI |
| Hemodialysis | Standard dose after each session | 3 times per week, post-dialysis | Per indication | ~23% removed during standard 3-hour HD session |
Cefpodoxime proxetil tablets should be administered with food to enhance absorption (AUC increases 21–33% with food). In contrast, the oral suspension may be given without regard to meals — the AUC and Cmax are similar in fed and fasted states for the suspension. This distinction is clinically important for patient counselling.
Pharmacology
Mechanism of Action
Cefpodoxime proxetil is an orally administered prodrug that undergoes de-esterification in the intestinal wall to release the active moiety, cefpodoxime. Like other cephalosporins, cefpodoxime is bactericidal through inhibition of bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting the transpeptidation step of peptidoglycan assembly. This results in cell wall instability and osmotic lysis. Cefpodoxime demonstrates stability against many beta-lactamase enzymes produced by gram-negative organisms, including those from H. influenzae, M. catarrhalis, and N. gonorrhoeae. It has broader gram-negative coverage than first- and second-generation cephalosporins, including activity against E. coli, K. pneumoniae, and P. mirabilis.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | Prodrug absorbed ~50%; Tmax 2–3 h; Cmax 1.4 mcg/mL (100 mg), 2.3 mcg/mL (200 mg), 3.9 mcg/mL (400 mg); food increases AUC 21–33% for tablets | Tablets require food for optimal absorption; suspension does not; dose-normalized bioavailability decreases slightly with higher doses |
| Distribution | Protein binding 22–33%; penetrates skin blister fluid, tonsils, lung tissue, middle ear fluid | Low protein binding means free drug concentrations are relatively high; achieves therapeutic levels at common respiratory and skin infection sites; no CSF data |
| Metabolism | Prodrug de-esterified to active cefpodoxime in intestinal wall; minimal further metabolism in vivo; no CYP involvement | Low drug-drug interaction potential via metabolic pathways; no hepatic dose adjustment required |
| Elimination | t½ 2.1–2.8 h (normal), 3.5 h (mild RI), 5.9 h (moderate RI), 9.8 h (severe RI); 29–33% excreted unchanged in urine; 23% removed by hemodialysis | Predominantly renal elimination; dose interval extension to q24h needed when CrCl <30 mL/min; supplemental dosing required post-hemodialysis |
Side Effects
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Diarrhea (at 800 mg/day) | 10.4% | At the FDA-approved skin infection dose of 400 mg BID; strongly dose-related. Rate drops to 5.7% at 200 mg/day. Of affected patients, 10% had C. difficile organisms or toxin detected in stool. In infants/toddlers <2 years receiving suspension, incidence was 12.8%. |
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Diarrhea (overall, all doses) | 7% (adults); 6% (peds) | Overall rate across all recommended dosing regimens (100–400 mg q12h); dose-dependent as noted above |
| Nausea | 3.3% | Taking tablets with food may reduce GI discomfort while also enhancing absorption |
| Vomiting (pediatric) | 2.3% (peds) | Higher in younger children; ensure adequate fluid intake |
| Diaper rash / fungal skin rash (pediatric) | 2% (peds) | Includes moniliasis; 8.5% in infants/toddlers <2 years |
| Other skin rashes (pediatric) | 1.8% (peds) | Distinguish from true drug allergy; diaper rash is more common in young infants |
| Vulvovaginal infections | 1.3% (women) | Typical class effect of broad-spectrum cephalosporins |
| Abdominal pain | 1.2% | Monitor for C. difficile if persistent or worsening |
| Vaginal fungal infections | 1% (women) | Related to disruption of normal vaginal flora |
| Headache | 1% | Typically mild and self-limiting |
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Anaphylactic shock | Rare | Minutes to hours after dosing | Discontinue immediately; administer epinephrine and emergency supportive care; permanent discontinuation |
| C. difficile-associated diarrhea / pseudomembranous colitis | Uncommon | During or up to 2+ months after therapy | Discontinue cefpodoxime; stool C. difficile testing; treat with oral vancomycin or fidaxomicin; one death attributed to pseudomembranous colitis with DIC reported post-marketing |
| Stevens-Johnson syndrome / toxic epidermal necrolysis | Very rare | 1–3 weeks after initiation | Immediate discontinuation; dermatology consultation; supportive care; never re-challenge |
| Serum sickness-like reaction | Rare | 7–21 days | Discontinue; anti-inflammatory treatment; avoid beta-lactam re-challenge |
| Acute liver injury | Very rare | Days to weeks | Discontinue; check LFTs; hepatology referral if jaundice or significant elevations |
| Hemolytic anemia / agranulocytosis | Very rare (class effect) | Variable | Discontinue; direct Coombs test; CBC with differential; hematology consultation |
| Seizures (class effect) | Very rare | Usually with renal impairment and unadjusted dosing | Discontinue; anticonvulsant therapy if indicated; verify appropriate renal dose adjustment |
| Reason for Discontinuation | Incidence | Context |
|---|---|---|
| GI disturbances | ~1.4% (adults) | N = 4,696 adult patients; 93 of 178 total discontinuations were GI-related |
| All adverse events combined | 2.7% (adults); 1.1% (peds) | Dose-related: significantly more discontinuations at 800 mg/day |
Diarrhea was the most frequently reported adverse event in cefpodoxime trials, with a notable dose-response relationship. Of adults with diarrhea, 10% had C. difficile organisms or toxin detected in stool. Do not prescribe anti-motility agents empirically until C. difficile has been excluded. CDAD has been reported to occur up to two months after antibiotic discontinuation and one postmarketing death was attributed to pseudomembranous colitis with disseminated intravascular coagulation.
Drug Interactions
Cefpodoxime undergoes minimal metabolism in vivo and has no CYP enzyme involvement. The primary clinically significant interactions involve agents that alter gastric pH, which is critical for dissolution of the cefpodoxime proxetil prodrug.
Cephalosporins, including cefpodoxime, can occasionally induce a positive direct Coombs’ test without clinical hemolysis. Transient changes in hepatic enzymes (AST, ALT, GGT, alkaline phosphatase, bilirubin, LDH), hematologic parameters (eosinophilia, leukopenia, thrombocytopenia, prolonged PT/PTT), and serum chemistry (hyperglycemia, hyperkalemia, hyponatremia) have been reported in trials without clear drug causality.
Monitoring
- Renal FunctionBaseline
RoutineSerum creatinine and estimated CrCl before initiation, particularly in elderly patients and those with known renal disease. Dose interval extension required when CrCl <30 mL/min. - Stool CharacterThroughout therapy
RoutineCounsel patients to report watery or bloody stools. In cefpodoxime clinical trials, 10% of patients with diarrhea had C. difficile in stool. Testing is indicated for severe or persistent diarrhea. - Clinical Response48–72 h after start
RoutineAssess for clinical improvement. If no response by 72 hours, re-evaluate diagnosis and consider culture-directed therapy. - Allergic ReactionsFirst dose and ongoing
Trigger-basedObserve for rash, urticaria, angioedema, or respiratory distress, especially in patients with penicillin allergy history (cross-reactivity may occur in up to 10%). - Hepatic FunctionIf symptoms arise
Trigger-basedTransient LFT elevations were reported in trials. Check LFTs if jaundice, dark urine, or abdominal pain develops. Acute liver injury reported post-marketing. - CBC with DifferentialProlonged courses
Trigger-basedConsider monitoring for eosinophilia, leukopenia, neutropenia, or thrombocytopenia during courses exceeding 14 days. Positive Coombs’ test reported as a class effect.
Contraindications & Cautions
Absolute Contraindications
- Known allergy to cefpodoxime or any cephalosporin antibiotic
Relative Contraindications (Specialist Input Recommended)
- History of severe penicillin allergy (anaphylaxis, bronchospasm) — cross-reactivity may occur in up to 10%; allergy evaluation recommended before prescribing
- Severe renal impairment without dose interval adjustment — t½ increases to 9.8 h; must extend to q24h when CrCl <30 mL/min
Use with Caution
- History of GI disease, especially colitis — elevated C. difficile risk; 10% of patients with diarrhea in trials had C. difficile
- Concurrent acid-suppressive therapy (PPIs, H2-blockers) — significantly reduces cefpodoxime absorption; consider alternative antibiotic
- Concurrent use of potent diuretics — may precipitate renal impairment and drug accumulation
- Infants <2 months of age — safety and efficacy not established
- Preexisting coagulopathy — cephalosporins may rarely cause hypothrombinemia and bleeding
Serious and occasionally fatal hypersensitivity reactions have been reported in patients receiving beta-lactam antibiotics. Cross-hypersensitivity among beta-lactam antibiotics has been clearly documented and may occur in up to 10% of penicillin-allergic patients. A careful inquiry into previous hypersensitivity reactions should be made before initiating therapy. If an allergic reaction occurs, discontinue immediately and institute appropriate emergency treatment.
Patient Counselling
Purpose of Therapy
Cefpodoxime is an antibiotic that kills bacteria by disrupting their protective cell wall. It treats bacterial infections only and will not help with viral illnesses such as colds or flu. Completing the full prescribed course is essential to clearing the infection and preventing antibiotic resistance.
How to Take
For tablets, always take with food — this significantly improves absorption. For the liquid suspension, food is not required; shake the bottle well before each dose and measure with a calibrated oral syringe or dosing cup. Store reconstituted suspension in the refrigerator and discard after 14 days. Take doses at evenly spaced intervals (every 12 hours).
Sources
- Cefpodoxime Proxetil Tablets, USP Prescribing Information. Ascend Laboratories, LLC. DailyMedPrimary source for adult dosing, pharmacokinetics, adverse events (N=4,696), drug interactions, and renal dosing adjustments.
- Cefpodoxime Proxetil for Oral Suspension USP Prescribing Information. Rising Pharma Holdings, Inc. Revised May 2025. DailyMedPrimary source for pediatric dosing, suspension pharmacokinetics, and pediatric adverse event data (N=2,128).
- Vantin (cefpodoxime proxetil) Tablets and Oral Suspension FDA Label, NDA 050674/050675. U.S. Food and Drug Administration. FDA.govOriginal brand-name labeling with clinical study results for pneumonia, pharyngitis, otitis media, and cystitis.
- Pichichero ME, Gooch WM, Rodriguez W, et al. Effective short-course treatment of acute otitis media using single daily dosing of cefpodoxime proxetil. Pediatr Infect Dis J. 1996;15(6):473-478. DOIEstablished efficacy of short-course cefpodoxime BID for pediatric AOM, supporting the 5-day regimen.
- Gehanno P, N’Guyen L, Derriennic M, et al. Pathogens isolated during treatment failures in otitis media. Pediatr Infect Dis J. 1998;17(10):885-890. DOIComparative data on pathogen eradication rates with cefpodoxime vs other beta-lactams in pediatric AOM.
- Lieberthal AS, Carroll AE, Chonmaitree T, et al. The diagnosis and management of acute otitis media. Pediatrics. 2013;131(3):e964-e999. DOIAAP guideline recommending cefpodoxime as an alternative agent for AOM in penicillin-allergic children.
- Chow AW, Benninger MS, Brook I, et al. IDSA clinical practice guideline for acute bacterial rhinosinusitis in children and adults. Clin Infect Dis. 2012;54(8):e72-e112. DOIIDSA guideline noting cefpodoxime plus clindamycin as a second-line option for sinusitis; monotherapy not recommended due to variable pneumococcal resistance.
- Shulman ST, Bisno AL, Clegg HW, et al. Clinical practice guideline for the diagnosis and management of group A streptococcal pharyngitis: 2012 update by the IDSA. Clin Infect Dis. 2012;55(10):e86-e102. DOIPositions cefpodoxime as an acceptable alternative for GAS pharyngitis in patients with non-anaphylactic penicillin allergy.
- Bradley JS, Byington CL, Shah SS, et al. The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the PIDS and IDSA. Clin Infect Dis. 2011;53(7):e25-e76. DOIPIDS/IDSA CAP guideline listing cefpodoxime among oral cephalosporin alternatives for H. influenzae infections.
- Wiseman LR, Todd PA. Cefpodoxime proxetil: a review of its antibacterial activity, pharmacokinetic properties and therapeutic potential. Drugs. 1994;47(5):784-822. DOIComprehensive review of cefpodoxime pharmacology, spectrum of activity, and clinical efficacy across indications.
- Borin MT. A review of the pharmacokinetics of cefpodoxime proxetil. Drugs. 1991;42(Suppl 3):13-21. DOIDetailed pharmacokinetic characterization including bioavailability, renal elimination, and effects of food and renal impairment.
- Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31-41. DOIFoundational CrCl estimation formula referenced in the cefpodoxime PI for renal dose adjustment guidance.
- Fulton B, Perry CM. Cefpodoxime proxetil: a review of its use in the management of bacterial infections in paediatric patients. Paediatr Drugs. 2001;3(2):137-158. DOIComprehensive review of pediatric pharmacokinetics, clinical efficacy, and safety across AOM, pharyngitis, and respiratory infections.